Prevail Therapeutics is a brand that is dedicated to improving patient outcomes in the field of neurodegenerative disorders. They are focused on developing a pipeline of gene therapies that aim to slow or stop the underlying disease process for patients with Parkinson's disease and other similar conditions. By leveraging recent breakthroughs in human genetics, Prevail Therapeutics targets potential disease-modifying targets for these neurodegenerative diseases.

Their precision medicine approach is designed to meet the urgent unmet needs of patient populations where there are currently no available therapies that can modify the progressive course of their disorders. Prevail Therapeutics collaborates with a range of partners, including REGENXBIO and The Silverstein Foundation for Parkinson's with GBA, to advance their pipeline of gene therapy programs. With a world-class leadership team, partners, and investors, Prevail Therapeutics is dedicated to eradicating Parkinson's disease and related disorders.

As a wholly owned subsidiary of Eli Lilly and Company, Prevail Therapeutics is headquartered in New York City and operates out of the Alexandria Center for Life Science. For more information, please visit the Eli Lilly website